Malmö-based Pila Pharma has announced the final outcome of its TO2 warrants. Despite a tough climate where the stock traded below the exercise price, the subscription rate landed at roughly 12 per cent, bringing in SEK 5,4 million. The capital injection tops-up an already solid balance sheet, securing the funding for the full upcoming clinical obesity study and extending the company’s financial runway well into 2027.
Read the full article at biostock.se:
https://biostock.se/en/2026/02/pila-pharma-starker-kassan-och-finansierar-klinisk-fetmastudie/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
© Modular Finance, source Nordic Press Releases